Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talazoparib - Pfizer

Drug Profile

Talazoparib - Pfizer

Alternative Names: BMN-673; BMN-673ts; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate; TALZENNA

Latest Information Update: 26 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEAD Therapeutics
  • Developer BioGene Pharmaceutical; Center Trials & Treatment; National Cancer Institute (USA); Pfizer; St. Jude Childrens Research Hospital; University of California at San Francisco; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Breast cancer
  • Phase III Ovarian cancer; Prostate cancer
  • Phase II Solid tumours; Squamous cell cancer
  • Phase I/II Acute myeloid leukaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 20 Nov 2018 Zenith Epigenetics and Pfizer enter into a clinical trial collaboration for a phase Ib/II trial for Breast cancer
  • 20 Nov 2018 Zenith Epigenetics plans a phase Ib/II trial for Breast cancer (Metastatic disease, Combination therapy, Late-stage disease) in the US
  • 06 Nov 2018 Nektar Therapeutics enters into an oncology clinical collaboration with Pfizer for Cancer (Combination therapy), including Prostate cancer (metastatic castration-resistant) and Head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top